drugset / Trial / NCT03684772

Topical Ionic Contra-Viral Therapy in Actinic Keratosis

NCT03684772

Phase 2 Unknown 32 enrolled Maruho Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.

Timeline

Start
2018-10-22
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.125 % Topical
Subject Furosemide Other / unclassified 0.125 % Topical

Indications